Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 5;39(8):1081–1090.e2. doi: 10.1016/j.ccell.2021.06.002

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Elsevier Inc.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Association of anti-SARS-CoV-2 spike IgG with immunosuppressive therapies

(A and B) Anti-spike protein IgG antibody titers (AU/mL) after full vaccination did not significantly differ in patients having received stem cell transplantation (SCT) (A) or anti-CD38 antibody therapy (B) when compared with respective counterparts.

(C and D) Patients receiving anti-CD20 antibody treatments (C) or CAR-T cell therapy (D) had a significantly lower titer after vaccination when compared with respective counterparts.

Box plots are shown with differences assessed by Kruskal-Wallis test.